ClinicalTrials.Veeva

Menu
P

Prolato Clinical Research Center | Houston, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

LNP023
Atrasentan
Obinutuzumab
Ianalumab
Secukinumab
SAR441344
GFB-887
Amlitelimab
VX-147
RO7434656

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

37 of 56 total trials

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

The purpose of this study is to evaluate efficacy, safety and tolerability of s.c. ianalumab administered in participants with diffuse cutaneous syst...

Enrolling
Diffuse Cutaneous Systemic Sclerosis
Drug: Ianalumab
Drug: Placebo

The purpose of this study is to measure the efficacy and safety of HZN-1116 in participants with Sjogren's syndrome (SS).

Enrolling
Sjogren's Syndrome
Drug: HZN-1116
Drug: Placebo

The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythemat...

Begins enrollment this month
Active Refractory Rheumatoid Arthritis
Systemic Lupus Erythematosus
Drug: Blinatumomab
Drug: Inebilizumab

The purpose of this study is to measure the long-term safety and tolerability of ianalumab in participants with Sjogrens syndrome who have previously...

Enrolling
Sjogrens Syndrome
Other: Placebo
Drug: Ianalumab (VAY736)

The purpose of this study is to evaluate the long-term safety and tolerability, of open label iptacopan in primary IgA nephropathy participants who h...

Enrolling
Primary IgA Nephropathy
Drug: LNP023

This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared with tacrolimus in participants w...

Active, not recruiting
Primary Membranous Nephropathy
Drug: Tacrolimus
Drug: Methylprednisolone

The goal of this clinical trial is to evaluate the safety and tolerability of felzartamab plus standard of care in participants with refractory Lupus...

Enrolling
Lupus Nephritis
Drug: Felzartamab

The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and...

Enrolling
Multiple Sclerosis
Drug: LY3541860
Drug: Placebo
Locations recently updated

This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE).

Enrolling
Systemic Lupus Erythematosus
Drug: Placebo
Drug: Obexelimab

The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and...

Enrolling
Chronic Kidney Diseases
Type 2 Diabetes Mellitus
Biological: Renal Autologous Cell Therapy (REACT)
Procedure: Sham Comparator

The goal of the Phase 3a part of this clinical trial is to determine the optimal dose that will be used in the Phase 3b part of this clinical trial....

Enrolling
Primary Membranous Nephropathy
Drug: SNP-ACTH (1-39) Gel
Drug: Rituximab

This is a parallel group, Phase 2, randomized, double-blind, placebo controlled, 5-arm, international, multicenter, 12-week proof of concept, dose fi...

Active, not recruiting
Rheumatoid Arthritis
Drug: SAR441566
Drug: Placebo

Primary Objective:To evaluate the effect of dazodalibep on systemic manifestations of Sjögren's Syndrome (SS) in participants with moderate-to-severe...

Enrolling
Sjogren's Syndrome
Drug: Dazodalibep
Drug: Placebo

This parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of obinutuzumab versus placebo in participants with...

Active, not recruiting
Systemic Lupus Erythematosus
Drug: Methylprednisolone
Drug: Acetaminophen/Paracetamol

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO...

Enrolling
Primary IgA Nephropathy
Drug: sefaxersen (RO7434656)
Drug: Placebo

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm monotherapy study for treatment of...

Enrolling
Dermatitis Atopic
Drug: Placebo
Drug: Amlitelimab

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 yea...

Enrolling
Dermatitis Atopic
Drug: Placebo
Drug: Amlitelimab

The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to e...

Enrolling
Primary Membranous Nephropathy
Drug: Tacrolimus
Drug: Zanubrutinib

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). T...

Enrolling
Lupus Erythematosus, Systemic
Drug: Placebo
Drug: Litifilimab

This is a phase 2 study to evaluate the effects of sibeprenlimab 400 mg administered subcutaneously (SC) every 4 (Q4) weeks as an add-on to backgroun...

Not yet enrolling
Sjogren Disease
Biological: Sibeprenlimab
Other: Placebo

Trial sponsors

Novartis logo
Sanofi logo
Amgen logo
Novo Nordisk logo
Pfizer logo
Roche logo
Vertex Pharmaceuticals logo
G
A
BeiGene logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems